SB 202190

Also known as: SB202190, SB-202190, FHPI, 4-(4-Fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)-1H-imidazole, 4-[4-(4-Fluorophenyl)-5-(pyridin-4-yl)-1H-imidazol-2-yl]phenol, 4-[5-(4-Fluorophenyl)-4-(pyridin-4-yl)-1H-imidazol-2-yl]phenol

SB 202190 (CAS 152121-30-7) is a compound in the Pharma Intermediates category listed in the Jingsj chemical database. It has the molecular formula C20H14FN3O and a molecular weight of 331.343 g/mol. Key properties include a melting point of 240-243℃, a boiling point of 565.7±50.0 °C at 760 mmHg, a density of 1.3±0.1 g/cm3 and a flash point of 295.9±30.1 °C. No supplier offers are currently listed; request a quote. Record last updated Aug 21, 2026.

CAS No.: 152121-30-7
Jingsj CID: J-1959011-5
Molecular Formula: C₂₀H₁₄FN₃O
Molecular Weight: 331.343 g/mol
Category: Pharma Intermediates
Last updated: 8/21/2026

Request MSDS / TDS

No offers for this compound yet.

Request a quote

Physicochemical Properties

Melting Point	240-243℃
Boiling Point	565.7±50.0 °C at 760 mmHg
Density	1.3±0.1 g/cm3
Flash Point	295.9±30.1 °C
Exact Mass	331.112091
PSA	61.80000
LogP	5.00
Vapor Pressure	0.0±1.6 mmHg at 25°C
Refractive Index	1.653
Storage Conditions	2-8°C

Activity & Biological Data

Target	IC50: 50 nM (p38), 100 nM (p38β2)[1]
Additional Information	[1]. Davies SP, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. [2]. Nemoto S, et al. Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase. J Biol Chem. 1998 Jun 26;273(26):16415-20. [3]. Grossi V, et al. Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response. Cancer Biol Ther. 2012 Dec;13(14):1471-81. [4]. Yang S, et al. Protective effects of p38 MAPK inhibitor SB202190 against hippocampal apoptosis and spatial learning and memory deficits in a rat model of vascular dementia. Biomed Res Int. 2013;2013:215798. [5]. Zhang Y, et al. PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer. EBioMedicine. 2015 Nov 19;2(12):1944-56.

Target

IC50: 50 nM (p38), 100 nM (p38β2)[1]

Additional Information

[1]. Davies SP, et al. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105. [2]. Nemoto S, et al. Induction of apoptosis by SB202190 through inhibition of p38beta mitogen-activated protein kinase. J Biol Chem. 1998 Jun 26;273(26):16415-20. [3]. Grossi V, et al. Sorafenib inhibits p38α activity in colorectal cancer cells and synergizes with the DFG-in inhibitor SB202190 to increase apoptotic response. Cancer Biol Ther. 2012 Dec;13(14):1471-81. [4]. Yang S, et al. Protective effects of p38 MAPK inhibitor SB202190 against hippocampal apoptosis and spatial learning and memory deficits in a rat model of vascular dementia. Biomed Res Int. 2013;2013:215798. [5]. Zhang Y, et al. PP2AC Level Determines Differential Programming of p38-TSC-mTOR Signaling and Therapeutic Response to p38-Targeted Therapy in Colorectal Cancer. EBioMedicine. 2015 Nov 19;2(12):1944-56.

Frequently Asked Questions

What is the CAS number of SB 202190?

The CAS number of SB 202190 is 152121-30-7.

What are the molecular formula and molecular weight of SB 202190?

SB 202190 has molecular formula C20H14FN3O and molecular weight 331.343 g/mol.

What are the upstream and downstream products of SB 202190?

For SB 202190, Upstream Products: 4-Fluoro-N-methoxy-N-methylbenzamide, 4-(tert-Butyldimethylsilyloxymethyl)pyridine, 4-Methylpyridine.

Data compiled from public chemical databases such as PubChem and supplier catalogs; supplier offers are provided by suppliers.

Last updated: 8/21/2026

How to cite: Jingsj. "SB 202190 (CAS 152121-30-7)". Jingsj Chemical Database. https://www.jingsj.com/compound/J-1959011-5 (accessed 2026-11-09).

Data for reference only; verify product details with suppliers before purchase.